Elicera Therapeutics Q4: Eventful 2025 ahead - Redeye
Bildkälla: Stockfoto

Elicera Therapeutics Q4: Eventful 2025 ahead - Redeye

Redeye returns following Elicera's Q4 report and recent news in the company. We largely reiterate our stance, but make some additional changes to our valuation, leading to a slight increase in our base case.

Redeye returns following Elicera's Q4 report and recent news in the company. We largely reiterate our stance, but make some additional changes to our valuation, leading to a slight increase in our base case.
Börsvärldens nyhetsbrev
ANNONSER